CECT Abdomen — Interpretation & Management Plan

Summary of Key Findings

The Central Question: What is Causing Gross Splenomegaly?

Priority Differential Diagnosis

1. Myeloproliferative Neoplasms (MPN)
   • Primary Myelofibrosis (PMF) — commonest cause of truly massive splenomegaly
   • Polycythemia Vera (PV)
   • Essential Thrombocythemia (ET)
   • CML (Chronic Myeloid Leukemia)
2. Lymphoproliferative Disease
   • Non-Hodgkin Lymphoma (especially splenic marginal zone lymphoma)
   • Chronic Lymphocytic Leukemia (CLL)
   • Hairy Cell Leukemia
3. Portal Hypertension / Congestive Splenomegaly
   • Cirrhosis with portal hypertension
   • Non-cirrhotic portal fibrosis

• Visceral Leishmaniasis (Kala-azar) — endemic regions
• Storage diseases (Gaucher's) — though rare at 68 years

The co-existence of cholelithiasis raises the possibility of hemolytic component (pigment stones from chronic hemolysis in MPNs or hemolytic anemias).

The tortuous splenic vein suggests elevated portal pressure or long-standing splenic engorgement.

Immediate Evaluation Protocol

1. Laboratory Investigations (Urgent)

• CBC: look for leuco-erythroblastic picture (tear-drop cells = myelofibrosis), cytopenias (hypersplenism), leukocytosis (CML/leukemia), thrombocytosis (ET/PV)
• Peripheral blood smear: dacrocytes, nucleated RBCs, blasts
• Reticulocyte count
• LDH, uric acid (tumor burden / cell turnover)
• Liver function tests, bilirubin (direct vs indirect — hemolysis vs cholestasis)
• PT/INR, coagulation profile

• JAK2 V617F mutation — positive in ~95% PV, ~50% PMF and ET
• BCR-ABL1 (Philadelphia chromosome) — to rule out CML
• CALR, MPL mutations — if JAK2 negative (PMF/ET)
• Serum EPO level (elevated in secondary causes, suppressed in PV)
• Vitamin B12 (markedly elevated in CML/PV)

• Bone marrow aspiration + trephine biopsy — essential for definitive diagnosis of myelofibrosis (fibrosis grading MF-0 to MF-3), lymphoma, leukemia

• Serum protein electrophoresis (SPEP)
• Flow cytometry (lymphoproliferative disease)
• LDH, β2-microglobulin
• Viral serology: HBsAg, Anti-HCV, HIV (if portal hypertension suspected)
• Leishmania serology / rK39 strip test (if endemic area)

2. Imaging — Further Workup

• USG Doppler abdomen: Assess portal vein caliber, hepatic echotexture, flow direction — evaluate for portal hypertension; assess splenic vein thrombosis more carefully
• Upper GI Endoscopy: Screen for esophageal/gastric varices if portal hypertension is suspected
• PET-CT: If lymphoma is high on differential (staging + metabolic activity)
• Echocardiography: If cardiac source of emboli is considered for the infarct

3. Assess for Hypersplenism

• Sequestration-related cytopenias (anemia, thrombocytopenia, neutropenia) — guide transfusion needs and surgical decision-making

Splenic Infarct — Management

"Treatment is conservative and splenectomy should be considered only when a septic infarct causes an abscess."

Conservative Management:

• Analgesia: NSAIDs / opioids for left upper quadrant / left shoulder tip pain
• Hydration: Adequate IV/oral hydration
• Anticoagulation: Consider if thrombotic etiology suspected (thrombocytosis-driven microvascular occlusion in MPN), balanced against bleeding risk — hematology input essential
• Monitor for infarct expansion, abscess formation, or rupture (serial imaging if symptomatic)

Red Flags Warranting Urgent Re-imaging/Surgery:

• Fever with leukocytosis → septic infarct → abscess formation
• Sudden worsening pain → splenic rupture
• Hemodynamic instability

Splenomegaly — Treatment Strategy (After Diagnosis)

If Myelofibrosis (most likely cause of this degree of splenomegaly):

If CML:

• Tyrosine kinase inhibitors (Imatinib, Dasatinib, Nilotinib) — dramatically reduce spleen size

If Lymphoma:

• Staging + chemotherapy per lymphoma subtype (R-CHOP, BR, etc.)

If Portal Hypertension / Congestive:

• Treat underlying liver disease
• TIPS or surgical shunting for refractory cases
• Variceal management

Cholelithiasis

• No immediate intervention needed (no cholecystitis features on CECT)
• Elective cholecystectomy can be planned concomitantly with splenectomy if surgery is undertaken — standard practice to avoid future biliary complications
• If pigment stones confirmed (hemolytic etiology), treating the underlying hematologic condition reduces further stone formation

Pleural Effusion / Atelectasis

• Mechanical, secondary to the massively enlarged spleen elevating the left diaphragm
• Will resolve with treatment of underlying cause / spleen size reduction
• No independent pleural intervention needed unless symptomatic dyspnea develops

Proposed Management Algorithm

CECT Findings
     ↓
Urgent CBC + Peripheral Smear + LFT + LDH
     ↓
┌────────────────────────────────────┐
│ Leuco-erythroblastic picture?      │──Yes──→ Bone marrow biopsy
│ JAK2/BCR-ABL/CALR mutation?        │         → Myeloproliferative workup
│ Lymphocytosis/Lymphadenopathy?     │──Yes──→ Flow cytometry + PET-CT
│ Portal HTN features on Doppler?    │──Yes──→ GI endoscopy + Hepatology ref
└────────────────────────────────────┘
     ↓
Hematology/Oncology referral (urgent)
     ↓
Treat underlying cause
     ↓
Reassess spleen size + infarct at 3 months
     ↓
Surgical planning (splenectomy ± cholecystectomy) if:
  - Refractory cytopenias
  - Failed medical therapy
  - Abdominal discomfort/mechanical complications

Relevant CT Appearance — Splenic Infarct

Priority Actions Summary

1. Urgent hematology referral — degree of splenomegaly mandates specialist evaluation
2. CBC with smear + JAK2/BCR-ABL — within 24-48 hours
3. Bone marrow biopsy — once hematology review complete
4. Doppler USG abdomen — assess portal hemodynamics, splenic vein
5. Conservative management of infarct — analgesia, monitor for complications
6. Cholelithiasis — defer, manage electively
7. Multidisciplinary team — Hematology, Surgery, Gastroenterology

⚠️ Clinical note: At this spleen size, the risk of spontaneous splenic rupture is non-trivial. The patient should be counseled to avoid contact activities and return immediately for acute left-sided pain. Any planned procedures (including biopsy) should account for thrombocytopenia/coagulopathy risk.